The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

The Centers for Medicare & Medicaid Services reported ... beating its benchmark by 150 percentage points (see more details here). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company ...

Novo Nordisk's stock rose about 5% on Friday ... weight loss drugs such as Wegovy are not currently covered by Medicare and other insurance.